Lilly shares drop 5% ahead of FDA oral obesity pill decision
Yahoo Finance links the decline to the pending regulatory decision and competitive pressure from Novo Nordisk.
DO
By Daniel Okafor · Regulatory Correspondent
Mar 17 03:00 ETSource: Yahoo Finance
The wire
- 01Eli Lilly stock fell 5% as investors weighed an FDA decision on its oral obesity pill alongside rivalry with Novo Nordisk.
- 02An oral incretin approval would change supply and prescribing dynamics for clinics and pharmacies currently built around injectable GLP-1s.
- 03The report does not state the decision date or outcome; the regulatory result itself remains the item to watch.
From the source
Read at finance.yahoo.comEli Lilly Falls 5% — FDA Oral Obesity Pill Decision and Novo Nordisk Rivalry Weigh on Shares
